A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

NCT ID: NCT00355524

Last Updated: 2013-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-06-30
• Study Completion Date: 2011-03-31

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114 with ritonavir and other antiretroviral agents in treatment-experienced, human immunodeficiency virus (HIV)-1 infected children and adolescents.

Detailed Description

This is an open-label (all people know the identity of the intervention) and randomized (study drug assigned by chance) study to evaluate pharmacokinetics, safety, tolerability, efficacy, antiviral activity, immunology and resistance characteristics of TMC114 with ritonavir in treatment-experienced, HIV-1 infected children and adolescent participants. The study consists of 3 periods: Screening period (maximum 4 weeks); Treatment period (maximum 48 weeks); and Follow-up period (4 weeks). The Treatment period consists of two parts: Part-1 for pediatric dose selection and Part-2 for the recommendation of pediatric or adult dose. Part-1 was further divided into two groups: Group A with adult equivalent dose of TMC114 with ritonavir twice daily and Group B with 20-33 percent higher dose of TMC114 with ritonavir twice daily. The recommended dose will be selected based on short-term safety, tolerability, antiviral activity and pharmacokinetics at Week 2. Once selected, all Part-1 participants who will not be on the selected dose will be switched to the selected dose at their next visit and will continue the study up to 48 weeks in Part-2. Participants with less than or equal to 18 years at Week 48 visit, and continued to benefit from treatment with TMC114 and will be living in a country where TMC114 pediatric use is not yet part of the label, will have the opportunity to roll-over to the extension phase where they will continue to receive TMC114/ritonavir until the participant became 18 years and TMC114 will be available through the local Health Care Systems or until TMC114 is indicated for use in pediatrics. Efficacy will primarily be evaluated by virologic response. Participants' safety will be monitored throughout the study.

Conditions

HIV-1; HIV Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A with >= 20 kg to < 30 kg body weight

300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter \[mL\]) of ritonavir liquid (80 milligram/milliliter \[mg/ml\]) will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Group A with >= 30 kg to < 40 kg body weight

300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter \[mL\]) of ritonavir liquid (80 milligram/milliliter \[mg/ml\]) will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Group A with >= 40 kg to < 50 kg body weight

450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Group B with >= 20 kg to < 30 kg body weight

375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Group B with >= 30 kg to < 40 kg body weight

450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Group B with >= 40 kg to < 50 kg body weight

600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Participants with >= 50 kg body weight

600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.

Group Type: EXPERIMENTAL

TMC114

Intervention Type: DRUG

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Ritonavir

Intervention Type: DRUG

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Interventions

TMC114

TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.

Intervention Type: DRUG

Ritonavir

Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.

Intervention Type: DRUG

Other Intervention Names

Darunavir

Eligibility Criteria

Inclusion Criteria

• Participants with documented human immunodeficiency virus (HIV)-1 infection failing their current antiretroviral therapy
• Body weight for Part 1: greater than or equal to 20 Kilogram (kg) but less than 50 kg and body weight for Part 2: greater than or equal to 50 kg and from greater than or equal to 20 but less than 50 kg after pediatric dose selection
• Able to swallow the TMC114 tablet formulations, the ritonavir capsule formulation, and to tolerate the ritonavir liquid formulation
• Stable cluster of differentiation 4 (CD4+) percentage; that is no more than 5 percent decrease in CD4+ percentage between the Screening visit and the last available CD4+ measurement
• Female participants who are sexually active and able to become pregnant must use a safe and effective birth control method

Exclusion Criteria

• For Part 1: Use of the non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) efavirenz as part of the current regimen was not allowed and for Part 2: Use of efavirenz as part of the current regimen was allowed and use of any antiretroviral and non-antiretroviral investigational agents within 30 days prior to screening
• Presence of any currently active acquired immune deficiency syndrome (AIDS) defining illness (Category C conditions according to the Centers for Disease Control [CDC] Classification System for HIV Infection 1993 or according to the 1994 revised CDC Classification System for HIV infection in children less than 13 years of age)
• Pregnant or breastfeeding female participants
• Previous allergy or hypersensitivity to any excipients of the investigational medication (TMC114) or ritonavir
• Any Grade 3 or 4 toxicity as defined by the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tibotec Pharmaceuticals, Ireland

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tibotec Pharmaceuticals Limited, Ireland Clinical Trial

Role: STUDY_DIRECTOR

Tibotec Pharmaceuticals, Ireland

Locations

Los Angeles, California, United States

Washington D.C., District of Columbia, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Worcester, Massachusetts, United States

Philadelphia, Pennsylvania, United States

Memphis, Tennessee, United States

Buenos Aires, , Argentina

Belo Horizonte, , Brazil

Nova Iguaçu, , Brazil

Ribeirão Preto, , Brazil

Rio de Janeiro, , Brazil

Toronto, Ontario, Canada

Montreal, Quebec, Canada

Paris, , France

Bucharest, , Romania

Constanța, , Romania

Cape Town Cape, , South Africa

Durban, , South Africa

Johannesburg Gauteng, , South Africa

Esplugues de Llobregat, , Spain

Madrid, , Spain

Countries

United States; Argentina; Brazil; Canada; France; Romania; South Africa; Spain

References

Blanche S, Bologna R, Cahn P, Rugina S, Flynn P, Fortuny C, Vis P, Sekar V, van Baelen B, Dierynck I, Spinosa-Guzman S. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS. 2009 Sep 24;23(15):2005-13. doi: 10.1097/QAD.0b013e328330abaa.

Reference Type: RESULT

PMID: 19724191 (View on PubMed)

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=987&filename=CR002797_CSR.pdf

A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents

Other Identifiers

TMC114-C212

Identifier Type: -

Identifier Source: secondary_id

CR002797

Identifier Type: -

Identifier Source: org_study_id